The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data

被引：0
|
作者：
Jie-mei Gu
Li Wang
Hua Lin
De-cai Chen
Hai Tang
Xiao-lan Jin
Wei-bo Xia
Yun-qiu Hu
Wen-zhen Fu
Jin-wei He
Hao Zhang
Chun Wang
Hua Yue
Wei-wei Hu
Yu-juan Liu
Zhen-lin Zhang
机构：
[1] Metabolic Bone Disease and Genetic Research Unit,Department of Osteoporosis and Bone Diseases
[2] Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Department of Endocrinology
[3] Lab of Osteoporosis,Department of Orthopaedics
[4] Tianjin Hospital,Department of Endocrinology
[5] The Center of Research for Metabolic Bone Disease and The Affiliated Drum Tower Hospital of Medical School,Department of Endocrinology
[6] Nanjing University,undefined
[7] West China Hospital,undefined
[8] Sichuan University,undefined
[9] Beijing Shunyi Hospital,undefined
[10] General Hospital of People's Liberation Army Chengdu Military Region,undefined
[11] Key Laboratory of Endocrinology,undefined
[12] Ministry of Health,undefined
[13] Peking Union Medical College Hospital,undefined
[14] Chinese Academy of Medical Science,undefined
来源：
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词：
risedronate; pyridinyl bisphosphonate; postmenopausal osteoporosis; bone density; biological markers; adverse reaction; drug administration schedule; double-blind method; female;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：841 / 846
页数：5
相关论文
共 27 条
  • [1] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Gu, Jie-mei
    Wang, Li
    Lin, Hua
    Chen, De-cai
    Tang, Hai
    Jin, Xiao-lan
    Xia, Wei-bo
    Hu, Yun-qiu
    Fu, Wen-zhen
    He, Jin-wei
    Zhang, Hao
    Wang, Chun
    Yue, Hua
    Hu, Wei-wei
    Liu, Yu-juan
    Zhang, Zhen-lin
    [J]. ACTA PHARMACOLOGICA SINICA, 2015, 36 (07) : 841 - 846
  • [2] A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
    Michael R. McClung
    Claude-Laurent Benhamou
    Zulema Man
    Witold Tlustochowicz
    Jose R. Zanchetta
    Rachelle Eusebio
    Ana M. Balske
    Ellen Matzkin
    Wojciech P. Olszynski
    Robert Recker
    Pierre D. Delmas
    [J]. Calcified Tissue International, 2013, 92 : 59 - 67
  • [3] A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
    McClung, Michael R.
    Benhamou, Claude-Laurent
    Man, Zulema
    Tlustochowicz, Witold
    Zanchetta, Jose R.
    Eusebio, Rachelle
    Balske, Ana M.
    Matzkin, Ellen
    Olszynski, Wojciech P.
    Recker, Robert
    Delmas, Pierre D.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2013, 92 (01) : 59 - 67
  • [4] Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
    Ilter, E
    Karalok, H
    Tufekci, EC
    Batur, O
    [J]. CLIMACTERIC, 2006, 9 (02) : 129 - 134
  • [5] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. -L.
    Man, Z.
    Eusebio, R. A.
    Beary, J. F.
    Burgio, D. E.
    Matzkin, E.
    Boonen, S.
    Delmas, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299
  • [6] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M. R. McClung
    J. R. Zanchetta
    A. Racewicz
    C. Roux
    C.-L. Benhamou
    Z. Man
    R. A. Eusebio
    J. F. Beary
    D. E. Burgio
    E. Matzkin
    S. Boonen
    P. Delmas
    [J]. Osteoporosis International, 2013, 24 : 293 - 299
  • [7] The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1 year study results
    McClung, Michael R.
    Benhamou, Claude-Laurent
    Man, Zulema
    Tlustochowicz, Witold
    Zanchetta, Jose R.
    Matzkin, Ellen
    Olszynski, Wojciech P.
    Recker, Robert
    Delmas, Pierre D.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S217 - S218
  • [8] Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women.
    Burgio, D
    Russell, D
    Desliva, B
    Namour, F
    Thompson, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P32 - P32
  • [9] The efficacy and tolerability of a once-a-month dosing regimen of 150 mg risedronate for the treatment of postmenopausal osteoporosis - the merit-OP study
    Delmas, P. D.
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. L.
    Man, Z.
    Eusebio, R.
    Beary, J. F.
    Burgio, D. E.
    Boonen, S.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S327 - S327
  • [10] EFFICACY AND SAFETY OF ZOLEDRONIC ACID 5 MG IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: THE HORIZON PREVENTION STUDY
    McClung, Michael R.
    Miller, Paul
    Recknor, Christopher
    Ruzucky, Maryellen
    BucciRechtweg, Christina
    Yu, Sue
    Benhamou, Claude Laurent
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S212 - S213
123